5

reha.cognition.jpreha.cognition.jp/pdf/2-2/page002.pdfLuria B 3) galanthamine Jacobs B physostigmine b, 26) scopolamine Z Z Z 28) o Naritomi 29), ACh-E 59 L controlled blind study

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: reha.cognition.jpreha.cognition.jp/pdf/2-2/page002.pdfLuria B 3) galanthamine Jacobs B physostigmine b, 26) scopolamine Z Z Z 28) o Naritomi 29), ACh-E 59 L controlled blind study
Page 2: reha.cognition.jpreha.cognition.jp/pdf/2-2/page002.pdfLuria B 3) galanthamine Jacobs B physostigmine b, 26) scopolamine Z Z Z 28) o Naritomi 29), ACh-E 59 L controlled blind study
Page 3: reha.cognition.jpreha.cognition.jp/pdf/2-2/page002.pdfLuria B 3) galanthamine Jacobs B physostigmine b, 26) scopolamine Z Z Z 28) o Naritomi 29), ACh-E 59 L controlled blind study
Page 4: reha.cognition.jpreha.cognition.jp/pdf/2-2/page002.pdfLuria B 3) galanthamine Jacobs B physostigmine b, 26) scopolamine Z Z Z 28) o Naritomi 29), ACh-E 59 L controlled blind study
Page 5: reha.cognition.jpreha.cognition.jp/pdf/2-2/page002.pdfLuria B 3) galanthamine Jacobs B physostigmine b, 26) scopolamine Z Z Z 28) o Naritomi 29), ACh-E 59 L controlled blind study